Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 2
2015 4
2016 3
2017 5
2018 3
2020 2
2021 4
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers.
Muto S, Enta A, Maruya Y, Inomata S, Yamaguchi H, Mine H, Takagi H, Ozaki Y, Watanabe M, Inoue T, Yamaura T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Hamada K, Suzuki H. Muto S, et al. Among authors: osugi j. Biomedicines. 2023 Jan 12;11(1):190. doi: 10.3390/biomedicines11010190. Biomedicines. 2023. PMID: 36672698 Free PMC article. Review.
The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study.
Fukuhara M, Muto S, Inomata S, Yamaguchi H, Mine H, Takagi H, Ozaki Y, Watanabe M, Inoue T, Yamaura T, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Suzuki H. Fukuhara M, et al. Among authors: osugi j. Cancer Immunol Immunother. 2022 May;71(5):1129-1137. doi: 10.1007/s00262-021-03067-3. Epub 2021 Oct 1. Cancer Immunol Immunother. 2022. PMID: 34596720 Free PMC article.
Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004).
Takagi H, Zhao S, Muto S, Yokouchi H, Nishihara H, Harada T, Yamaguchi H, Mine H, Watanabe M, Ozaki Y, Inoue T, Yamaura T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Kanno R, Aoki M, Tan C, Shimoyama S, Yamazaki S, Kikuchi H, Sakakibara-Konishi J, Oizumi S, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Honjo O, Minami Y, Nishimura M, Dosaka-Akita H, Nakamura K, Inano A, Isobe H, Suzuki H. Takagi H, et al. Among authors: osugi j. Lung Cancer. 2021 Mar;153:134-142. doi: 10.1016/j.lungcan.2021.01.014. Epub 2021 Jan 14. Lung Cancer. 2021. PMID: 33508526 Free article.
Genetic alterations in epidermal growth factor receptor-tyrosine kinase inhibitor-naïve non-small cell lung carcinoma.
Yamaura T, Muto S, Mine H, Takagi H, Watanabe M, Ozaki Y, Inoue T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Suzuki H. Yamaura T, et al. Among authors: osugi j. Oncol Lett. 2020 Jun;19(6):4169-4176. doi: 10.3892/ol.2020.11524. Epub 2020 Apr 8. Oncol Lett. 2020. PMID: 32391110 Free PMC article.
Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden.
Muto S, Ozaki Y, Yamaguchi H, Mine H, Takagi H, Watanabe M, Inoue T, Yamaura T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Nanamiya H, Imai JI, Isogai T, Watanabe S, Suzuki H. Muto S, et al. Among authors: osugi j. Oncol Lett. 2021 Mar;21(3):203. doi: 10.3892/ol.2021.12464. Epub 2021 Jan 12. Oncol Lett. 2021. PMID: 33574942 Free PMC article.
26 results